Physician profile
Leigh Ellen Eubanks
NPI 1780681171
$5,259.19
in general payments reported to CMS, 2019-2025
30 companies · $605 in 2025
The $605 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $145 · 2021: $684 · 2022: $710 · 2023: $1,434 · 2024: $1,195 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.12 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,225.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $484.25 | 2021-2025 | |
| Janssen Biotech, INC. | $403.87 | 2020-2024 | Tremfya, Simponi, Stelara |
| Allergan, INC. | $347.23 | 2019-2022 | |
| Pfizer INC. | $280.80 | 2019-2023 | |
| Revance Therapeutics, INC. | $247.66 | 2024-2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $245.60 | 2019-2021 | |
| Lilly USA, LLC | $236.83 | 2021-2023 | Taltz |
| Galderma Laboratories, L.P. | $226.89 | 2020-2025 | Nemluvio, Aklief |
| Almirall LLC | $189.98 | 2022 | |
| Incyte Corporation | $159.68 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $135.48 | 2021-2024 | |
| Journey Medical Corporation | $132.24 | 2023 | |
| Leo Pharma INC. | $116.45 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $116.23 | 2022-2024 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $114.50 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $109.72 | 2023-2024 | Otezla |
| Genzyme Corporation | $108.86 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $89.85 | 2023-2025 | Zoryve |
| Dermira, INC. | $42.32 | 2019 | |
| Dermavant Sciences, INC. | $42.15 | 2024 | Vtama |
| Encore Dermatology INC. | $35.21 | 2019 | |
| Organon LLC | $32.55 | 2025 | Vtama |
| Krystal Biotech INC | $24.12 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $23.63 | 2023 | Ycanth |
| Medtronic USA, INC. | $23.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.81 | 2025 | Libtayo |
| Aclaris Therapeutics, INC. | $15.12 | 2019 | |
| Botanix Sb INC | $14.54 | 2025 | Sofdra |
| Hill Dermaceuticals, INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Ellen Eubanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.